RE:RE:RE:Bio..you have all the answers..Sure, to use more appropriate language, I couldn't agree more of your point of having financial data to support an agreement announcement, and that is a reasonable request and condition for the share price to be representative of the value to Sirona/shareholders.
Investors are by default naiive because nothing has been shared, we are all acting upon our own assumptions, and the shareprice is one fat guess at the net present value of the total package deal with Abbvie. At 18.5 cents, the market is valuing this as "zero" difference from the status quo prior to the announcement. The company has said that this deal will make them profitable, but nobody believes that for some reason, perhaps because of a lack of trust with management.
Well ok, it is what it is.